Supplementary Figures 1 and 2 and Supplementary Tables 1 through 3 from A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
Year: 2023
Type: supplementary-materials
Abstract: PDF - 1128K, Figure S1. Knockdown of CDK7 and CDK9 can inhibit RNAP II CTD P-Ser2 and P-Ser5. Figure S2. LY2857785 and flavopiridol inhibit MCL-1, XIAP protein expression and induce CASP-3 and cleaved PARP in AML cell MV-4-11. Table S1. LY2857785 inhibits solid tumor cell proliferation and induces apoptosis. Table S2. 261 probsets gene signature in sens and res cell lines. Table S3. LY2857785 inhibits proliferation of normal human hematopoietic cells in vitro.
Authors: Tinggui Yin, Maria J. Lallena, Emiko L. Kreklau, Kevin R. Fales, Santiago Carballares, Raquel Torrres, Graham N. Wishart, Rose T. Ajamie, Damien M. Cronier, Phillip W. Iversen, Timothy I. Meier, Robert T. Foreman, Douglas Zeckner, Sean E. Sissons, Bart W. Halstead, Aimee B. Lin, Gregory P. Donoho, Yuewei Qian, Shuyu Li, Song Wu, Amit Aggarwal, Xiang S. Ye, James J. Starling, Richard B. Gaynor, Alfonso de Dios, Jian Du
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362494090